An injectable soft implant for long-acting, reversible, ultra-stable release of therapeutics

This paper presents an injectable, retrievable "soft implant" composed of surface-eroding poly(orthoester) microparticles within a hydrogel that achieves long-term, zero-order release of therapeutics for over six months, offering a transformative solution for improving patient adherence in treatments requiring sustained dosing.

The Gist

Imagine you need to take a daily pill for a year to prevent pregnancy or manage a chronic illness. The problem? Remembering to take a pill every single day is hard. Miss a dose, and the protection stops. This is the "adherence problem" that plagues millions of patients.

Scientists have tried to solve this with long-acting implants (like the "Norplant" rods under the skin), but those usually require a surgeon to put them in and a surgeon to take them out. If you have a bad reaction or just want to get pregnant sooner, you're stuck waiting for a doctor's appointment and a scalpel.

The Solution: A "Smart" Injectable Gel

This paper describes a new invention called a "Soft Implant." Think of it not as a hard rod, but as a special gel that you can shoot into your arm with a regular needle (like a flu shot), but it works like a tiny, slow-release factory for up to a year.

Here is how it works, broken down into simple parts:

1. The "Smart Bricks" (The Microparticles)

Inside this gel are millions of tiny, microscopic spheres (about the width of a human hair). These aren't just random balls; they are made of a special plastic called Poly(orthoester) or POE.

• The Analogy: Imagine a loaf of bread. Most plastics (like the common PLGA used in other implants) are like a sponge. When you put a sponge in water, it gets soggy all the way through, and the medicine inside bursts out all at once or in weird fits and starts.
• The Innovation: These new POE "bricks" are like a sandstone wall. They are designed to erode only from the outside in. As the very outer layer dissolves, it reveals the next layer, releasing the medicine at a perfectly steady, slow pace. This is called "Zero-Order Release."
  • Real-world comparison: It's like a candle burning down. A candle doesn't melt faster as it gets shorter; it melts at the same steady rate from top to bottom. This implant does the same thing with medicine.

2. The "Delivery Truck" (The Hydrogel)

You can't just inject a pile of dry sand into someone; it would clog the needle and hurt. So, the scientists mixed these tiny "bricks" into a medical-grade gel (similar to the fillers used for lip augmentation).

• The Analogy: Think of the gel as a soft, squishy delivery truck. It holds the "bricks" safely in place.
• Why it matters: This gel makes the injection easy (no surgery needed) and, crucially, it makes the implant retrievable. If you change your mind or have a side effect, a doctor can make a tiny nick in the skin, squeeze the gel out, and pull the whole "truck" and its cargo out in one piece. It's like pulling a plug, but for a year-long medicine supply.

3. The "Tunable Dial"

One of the coolest parts of this research is that they can tune how long it lasts.

• By changing the chemical recipe of the "bricks" (the POE), they can make the wall dissolve faster or slower.
• They tested this with Levonorgestrel, a hormone used for birth control.
  • Some versions released medicine for 1 month.
  • Some for 6 months.
  • The best version is projected to last over 12 months (a whole year!) with a perfectly steady dose, no spikes, and no drops.

4. The Proof

The team tested this in rats and mice:

• Injectability: They shot it through a standard needle easily.
• Retrievability: They injected it, waited 60 days, and then pulled it out. The gel came out almost entirely intact, taking the medicine particles with it.
• Safety: The rats' bodies didn't reject it. There was very little inflammation, and the skin healed quickly.
• Performance: The rats had a steady level of the hormone in their blood for months, exactly like the scientists predicted.

Why This Changes Everything

Currently, if you want long-term birth control, you have to choose between:

1. Pills: Easy to take, but easy to forget.
2. IUDs/Implants: Very effective, but require a doctor to insert and remove them (invasive).
3. Injections: Easy to give, but only last 3 months (you have to go back every 3 months).

This "Soft Implant" offers a Goldilocks solution:

• Easy to give: Just a needle (no surgery).
• Long-lasting: Up to a year (no monthly visits).
• Reversible: Can be removed instantly if you want to stop.

The Bottom Line:
This technology turns a complex, surgical medical procedure into something as simple as getting a flu shot, but with the power of a year-long treatment. It could revolutionize how we treat not just birth control, but also diabetes, HIV prevention, and chronic pain, making long-term care easier, cheaper, and more reliable for everyone.

Technical Summary

1. Problem Statement

Long-term therapeutic regimens (e.g., for contraception, diabetes, or chronic diseases) often suffer from poor patient adherence due to the need for frequent dosing. While long-acting drug delivery systems exist, they face significant limitations:

• Invasiveness: Existing long-acting implants (>6 months) often require surgical insertion and removal.
• Release Kinetics: Common biodegradable polymers like PLGA (poly(lactic-co-glycolic acid)) exhibit "bulk erosion," leading to irregular release profiles characterized by initial "burst" effects and subsequent plateaus, rather than the desired zero-order (constant rate) release.
• Retrievability: Most long-acting systems cannot be easily removed if a patient wishes to discontinue therapy (e.g., to restore fertility) or experiences side effects.
• Generalizability: Current injectable long-acting systems often rely on specific drug chemistries (e.g., hydrophobic prodrugs or micronized crystals) that are difficult to generalize across different therapeutics.

2. Methodology

The authors developed a modular, injectable "soft implant" platform consisting of surface-eroding polymeric microparticles (MPs) embedded within a biodegradable hydrogel carrier.

• Polymer Design (POE Library):
  • The core technology utilizes Poly(orthoesters) (POEs), a class of surface-eroding polymers. Unlike bulk-eroding PLGA, POEs degrade via hydrolysis at the surface, preventing water penetration into the core and enabling zero-order release.
  • A library of POE formulations was synthesized using DETOSU (diketene acetal) reacted with various diols (e.g., hexanediol, decanediol, cyclohexanedimethanol, triethylene glycol, glycerol monomethacrylate, and piperazine diol).
  • Tuning Mechanism: Release rates were tuned by altering the hydrophilicity/hydrophobicity of the diol monomers and incorporating basic additives (e.g., Mg(OH)₂, PEI, MgSt) or tertiary amine-containing monomers (piperazine) to neutralize acidic degradation products, thereby slowing auto-catalytic degradation.
• Fabrication (Microfluidics):
  • Drug-loaded MPs were fabricated using a microfluidic flow-focusing device to ensure monodispersity (~80 µm diameter) and defect-free structures.
  • The active drug used as a model was Levonorgestrel (LNG), a contraceptive agent.
• Hydrogel Carrier:
  • MPs were embedded in a medical-grade Hyaluronic Acid (HA) hydrogel (Belotero® filler). This carrier enables:
    • Injectability: Passage through a standard 23G needle.
    • Retrievability: The hydrogel can be physically removed via a small incision.
    • Stability: The composite was freeze-dried and reconstituted for storage without losing homogeneity.
• Characterization:
  • In Vitro: Release studies in PBS at 37°C with cyclodextrin to maintain sink conditions. Raman confocal microscopy was used to map drug distribution and water ingress to confirm surface erosion mechanisms.
  • In Vivo: Pharmacokinetic (PK) studies were conducted in rats (Sprague-Dawley) and mice (BALB/c) to assess plasma concentration, injectability, and retrievability. Histopathology was performed to assess tissue response.

3. Key Contributions

• Surface-Eroding POE Microparticles: Demonstrated that molecularly tailored POE formulations can achieve sustained zero-order release for up to 12 months, overcoming the irregular release profiles of PLGA.
• Injectable and Retrievable Platform: Created a "soft implant" that combines the ease of injection (via 23G needle) with the reversibility of surgical implants. The hydrogel carrier allows for the physical removal of the entire drug depot if therapy needs to be terminated.
• Tunability: Showed that release kinetics can be precisely controlled from 1 month to >12 months by adjusting the polymer composition (diol ratios and additives) without changing the fundamental zero-order mechanism.
• Mechanistic Validation: Used Raman chemical mapping to provide direct visual evidence of surface erosion (stable drug signal, no water ingress) in POE MPs, contrasting it with the bulk erosion and swelling observed in PLGA MPs.

4. Key Results

• In Vitro Release:
  • POE-H3C6P1 (containing piperazine diol) demonstrated a stable zero-order release of LNG for 300 days (projected >12 months) with no initial burst.
  • Increasing drug loading from 5% to 10% (w/w) did not alter the release rate, confirming the surface-erosion mechanism.
  • In contrast, commercial PLGA (Resomer® RG 756 S) showed irregular release with a significant delayed burst after 120 days.
• In Vivo Pharmacokinetics (Rats):
  • Rats injected with the POE-H3C6P1 composite maintained stable plasma LNG concentrations for 161 days (the duration of the study), consistent with zero-order kinetics.
  • The release profile was independent of drug loading (5% vs. 10%), mirroring in vitro findings.
  • Compared to LNG crystals (which peaked rapidly and decayed), the POE composite provided a flat, sustained concentration profile.
• Injectability and Retrievability:
  • The composite was successfully injected through a 23G needle with an average force <20 N.
  • In mice, the implant was successfully retrieved via a small incision 60 days post-injection, removing ~90% of the fluorescent signal (indicating particle removal) with minimal tissue damage.
• Biocompatibility:
  • Histological analysis at 168 days showed minimal inflammation, no capsule formation, and intact epidermis, indicating the platform is well-tolerated.
  • Cytotoxicity assays on dermal fibroblasts confirmed the safety of both fresh and degraded POE MPs.

5. Significance

This work represents a significant advancement in long-acting drug delivery systems by addressing the "trilemma" of long duration, zero-order kinetics, and reversibility.

• Clinical Impact: The platform offers a potential solution for long-term contraception (replacing IUDs and implants with a needle-injectable, removable option) and could be adapted for chronic diseases requiring strict dosing schedules (e.g., diabetes, HIV PrEP, autoimmune disorders).
• Patient Adherence: By eliminating the need for frequent dosing and allowing for easy discontinuation, the system significantly improves patient autonomy and adherence.
• Scalability: The use of microfluidics and standard hydrogel carriers suggests the technology is scalable and adaptable to various therapeutic agents beyond LNG.

The study successfully bridges the gap between the stability of surface-eroding polymers and the convenience of injectable formulations, paving the way for next-generation "soft implants."